drugset / Trial / NCT00103337
Cilengitide in Treating Patients With Metastatic Prostate Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This randomized phase II trial is studying how well cilengitide works in treating patients with metastatic prostate cancer. Cilengitide may stop the growth of prostate cancer by blocking blood flow to the tumor
Timeline
- Start
- 2005-01
- Primary completion
- 2007-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | cilengitide | Peptide | 500 mg | Intravenous |
| Subject | cilengitide | Peptide | 2000 mg | Intravenous |